Amolyt Pharma

News & Media

Press Releases

Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting

September 12, 2022
Download a PDF: EN or FR

Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting

September 1, 2022
Download a PDF: EN or FR

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

June 29, 2022
Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
AZP-3601

KOL Webinar on AZP-3601 Featuring Professor István Takács

Written by
jpoly4
AZP-3601

Development of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ). ASBMR Poster.

Written by
Dan Hennings
AZP-3601

Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism

Written by
Dan Hennings
AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Presentation.

Written by
jpoly4
AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Poster.

Written by
jpoly4
AZP-3813

AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly

Written by
jpoly4
AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

Written by
walid
AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

Written by
Olivia
AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

Written by
walid
AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

Written by
walid
AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

Written by
jpoly4
AZP-3601

cHP Natural History Study: ISPOR Poster

Written by
jpoly4
AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Written by
jpoly4
AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Written by
jpoly4
AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Written by
jpoly4

Upcoming events

Date: November 1, 2022

Date: January 9-12, 2023 (San Francisco, CA)

Date: November 14- 16, 2022 (Harrogate, England)

Social Updates

TWITTER

Scroll to Top